Citations

Clear

1055 citation(s) found for "Small, J C".

Clinical Characteristics and Outcomes of Small Bowel Neoplasms in Crohn’s Disease: A Case-Control Study
Urquhart, Siri A. , Smyrk, Thomas C. , Harmsen, William S. , Coelho–Prabhu, Nayantara , Coelho-Prabhu, Nayantara , Loftus, Edward V. , Kisiel, John B.

Mayo Clinic

Crohn's & Colitis 360 | February 15, 2025 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/crocol/otaf001 | PMID 39959612 Get It

Abstract Background Patients with Crohn’s disease (CD) who have ileal or any small bowel (SB) involvement are at increased risk of developing SB cancer. Due to the rarity of this complication of CD, we aimed to describe the clinical features, presentation, and of small bowel neoplasms (SBN) in patients with CD. Methods A case-control study was performed to include patients ≥18 years old with a diagnosis of CD with or without SBN at a single large referral center from January 1992 to May 2023. Patients were identified using bioinformatics and natural language processing tools, as well as anatomic pathology records. Two age- and sex-matched controls were identified for each case. Results In total, 54 patients with CD and SBN and 108 patients with CD without SBN were identified. Of the cases, most had ileal CD (55.6%) with stricturing (59.3%) phenotype. Median duration of CD prior to SBN diagnosis was 19.5 years. Nonpenetrating/nonstricturing behavior (odds ratio [OR], 9.23; 95% CI, 2.91-29.32; P = .0008) was significantly associated with an increased odds of SBN. History of tobacco use (OR, 0.27; 95% CI, 0.13-0.60; P = .0011) and IBD-associated colonic neoplasia (OR, 0.18; 95%, CI 0.4-0.85; P = .0303) were protective in development of SBN. Conclusions Nonpenetrating/nonstricturing CD appeared to raise SBN risk. History of tobacco use and colonic IBD-associated neoplasia are associated with reduced risk of SBN. Further studies with large sample sizes are needed to determine true incidence and risk factors associated with SBN in CD and assess potentially protective effects of early surgery.
Executive Summary of the American Radium Society Appropriate Use Criteria for Management of Squamous Cell Carcinoma of the Cervical Esophagus
Cancer, Expert Panel Management of Cervical Esophageal, Williams, Vonetta M. , Hallemeier, Christopher L. , Shah, Pari , Anker, Christopher J. , Abood, Gerard, Akselrod, Dmitriy , Kennedy, Timothy J., Lee, Percy, Sharma, Navesh , William, Small, Russo, Suzanne , Russo, Suzanne , Cancer, Expert Panel Management of Cervical Esophageal, Hallemeier, Christopher Leigh , Jethwa, Krishan R. , Selfridge, Jennifer Eva , Berlin, Jordan D. , Kim, Ed, Lee, Percy , William, Small, Tchelebi, Leila T.

Mayo Clinic

American Journal of Clinical Oncology | February 6, 2025 | Volume: 48 | Issue: 4 | Pages: 163-179

10.1097/coc.0000000000001165 | PMID 39912327 Get It

Objectives: Cervical esophageal cancer (CEC) is an uncommon malignancy accounting for <5% of all esophageal carcinomas. Treatment of CEC varies and is adapted from established regimens used for squamous cell carcinoma (SCC) or the lower esophageal and head and neck. The present systematic review and guidelines are intended to assist treatment decision making for patients with CEC based on the available evidence. Methods: Using the Population, Intervention, Comparator, Outcome, Timing, and Study Design (PICOTS) framework, the evidence regarding treatment outcomes was assessed using Cochrane and PRISMA 2020 methodology. Eligible studies included prospective Phase II to III trials and retrospective analyses published between January 1, 2013 and February 23, 2024 in the Ovid Medline database. These references were assessed through the American Radium Society (ARS) Appropriate Use Criteria (AUC) methodology. A systematic review PRISMA 2020 checklist confirmed the completion of essential elements. RAND-UCLA consensus methodology was used by the expert panel to rate the appropriateness of the treatment options. Results: ARS AUC recommendations include (1) larynx preservation using endoscopic resection (EMR or ESD) alone for the typical case with pT1a cN0 cM0 CEC, (2) definitive CRT for the typical case with cT1bN0M0 in patients who cannot undergo endoscopic resection, (3) larynx-preserving using definitive CRT (with or without induction chemotherapy) for the typical case with nonmetastatic locally advanced CEC (advanced T-stage tumors or involved lymph nodes), with surgery reserved for those patients with incomplete response or locoregional recurrence. Conclusions: This ARS AUC summary provides guidelines for the management of SCC of the cervical esophagus provides based on available evidence. Topics that warrant further investigation include optimization of (1) patient selection; (2) multimodality therapies including chemotherapy, immunotherapy, and targeted agents; (3) radiation dose, schedule, and treatment volume; and (4) supportive care for patients with CEC. Ongoing trials continue to improve outcomes for patients with CEC.
Trends in the Incidence and Survival Outcomes in Patients With Small Cell Lung Cancer in the United States: An Analysis of the SEER Database
Uprety, Dipesh , Seaton, Randell, Niroula, Abesh , Parikh, Kaushal , Uprety, Dipesh , Hadid, Tarik H. , Ruterbusch, Julie J.

Mayo Clinic

Cancer Medicine | February 5, 2025 | Volume: 14 | Issue: 3 | Pages: No page available

10.1002/cam4.70608 | PMID 39908169 Get It

ABSTRACT Background There has been a lack of updated epidemiological data on the incidence and survival outcomes for patients with small cell lung cancer (SCLC) in the United States over the last two decades. Methods A retrospective, population‐based study was conducted utilizing the Surveillance, Epidemiology, and End Results (SEER) program to identify patients with SCLC from 2000 to 2020. Trends in cancer incidence, incidence‐based mortality rates, 1‐year relative survival rates and 1‐year observed survival were evaluated utilizing the SEER database. Results The database identified a total of 188,426 SCLC patients during the study period from 2000 through 2020. The age‐adjusted incidence rate slowly declined, on average, by 3% (95% CI: −3.2% to −2.8%) each year from 9 per 100,000 in 2000 to 4.6 per 100,000 in 2020. The decline is evident for all age groups, sexes, and races. Incidence‐based mortality also declined slowly from 6.6 in 2005 to 3.5 in 2020. However, survival outcomes, including 1‐year relative survival and 1‐year observed survivals, have not improved significantly over the last two decades. Conclusion This study found that the incidence of SCLC has decreased from 2000 to 2020, likely due to a reduction in smoking rates, underscoring the importance of smoking abstinence. An improvement in incidence‐based mortality is likely related to an enhanced medical care and a decrease in the incidence of SCLC, but the lack of improvement in survival outcomes reflects the need for more effective systemic therapy.
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis
Wood, Cameron , Lyniv, Liliana, Isaacs, James M, Kaufman, Jacob M., Oduah, Eziafa , Clarke, Jeff, Crawford, Jeffrey, Stinchcombe, Thomas E. , Tong, Betty , Wigle, Dennis A. , Dragnev, Konstantin H. , Antonia, Scott , Ready, Neal , Wigle, Dennis, Ready, Neal , Wood, Cameron , Isaacs, James , Wang, Xiaofei , Gu, Lin, Weinhold, Kent J.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | February 4, 2025 | Volume: 13 | Issue: 2 | Pages: e010395

10.1136/jitc-2024-010395 | PMID 39904561 Get It

Background Our study was designed to determine the safety, efficacy, and immunological effects of perioperative pembrolizumab in early-stage NSCLC. Methods This is a single-arm phase II study of perioperative pembrolizumab in patients with untreated, clinical stage IB to IIIA NSCLC. Patients received two doses of 200 mg pembrolizumab, surgery, standard adjuvant chemotherapy, followed by four doses adjuvant pembrolizumab. The primary objective of this study was to determine surgical feasibility rate, and secondary objectives are pathological response rate, treatment adverse events, efficacy data, and exploratory analysis of biomarkers. Results 30 patients initiated perioperative pembrolizumab, and 25 completed tumor resection. At median follow-up of 59 months after surgical resection, seven patients had disease progression, while six had died representing. A 5-year progression-free survival (PFS) from time of surgery was 72.0% (56.4%–91.9%) and overall survival (OS) from time of surgery was 75.8% (60.7%–94.7%). Major pathological response (MPR) was found in seven tumors (28%) including two complete responses (4%). Across all treated patients, four receiving neoadjuvant and four receiving adjuvant pembrolizumab experienced treatment-related adverse events of grade 3 or higher with no grade 5 events. Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) levels increased across our patient cohort over time from baseline until postsurgery and remained elevated at the end of treatment. There was a significant difference between mean plasma PCSK9 levels for patients with MPR versus all other patients on study when checked postoperatively. Conclusions Perioperative pembrolizumab was safe and effective with promising MPR rate, PFS, and OS.
Evolving Field of Immunotherapy: Pioneering New Paths in Small-Cell Lung Cancer
Hazim, Antonious , Leventakos, Konstantinos , Ernani, Vinicius , Hazim, Antonious Z , Ernani, Vinicius

Mayo Clinic

JCO Oncology Practice | February 3, 2025 | Volume: 21 | Issue: 7 | Pages: 942-949

10.1200/op-24-00862 | PMID 39899772 Get It

Small-cell lung cancer (SCLC) is an aggressive form of lung cancer that displays rapid proliferation and early metastatic potential. It accounts for approximately 15% of lung cancers and is strongly associated with tobacco carcinogens. Despite patients' initial response to systemic therapy, the majority develop early resistance and relapse. The outcomes of patients with metastatic SCLC are poor, prompting the need for new therapies. Over the past decade, the treatment landscape for NSCLC (non-small cell lung cancer) has significantly changed with the immergence of novel targeted therapies and immunotherapies. However, inroads of these therapies into SCLC have posed significant challenges due to its molecular and genomic heterogeneity. Despite the challenges of this disease, promising new first-in-class immunomodulatory agents have emerged and are currently undergoing extensive research. Herein, we review the current treatment paradigm of immunotherapy in SCLC and discuss future directions of this evolving field.
P-1501. Intracellular Activity of Delafloxacin Against Small Colony Variant Staphylococcus aureus
Tudahl, Kristen L, Thompson, Hailey, Wimmer, Megan R., Buss, Brian, Volk, Cecilia , Smith, Jeannina A. , Rosato, Adriana E.

Mayo Clinic

Open Forum Infectious Diseases | January 29, 2025 | Volume: 12 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofae631.1670 Get It

Abstract Background Small colony variants (SCVs) of Staphylococcus aureus (SA) have significant intracellular persistence. Fluoroquinolones demonstrate intracellular activity and are often utilized to treat SCVs. Delafloxacin is a fluroquinolone with increased potency at a low pH, which could lead to enhanced intracellular activity. This study evaluates delafloxacin activity against intracellular MSSA and MSRA SCV isolates.Figure 1.Illustration of SCV co-culture methods Methods Six clinical SCV-SA isolates were co-cultured with human macrophages for 1 hour, allowing for phagocytosis (Fig 1). The remaining extracellular bacteria were removed and antibiotic treatments of delafloxacin, levofloxacin, gentamicin, cefazolin, or vancomycin were added. After 5-hour and 24-hour incubation periods, supernatants were collected for extracellular colony forming unit (CFU) enumeration. Macrophages were washed, lysed, collected, and plated for intracellular bacterial CFU enumeration. All conditions were repeated in triplicate and compared using a Mann Whitney U test.Figure 2.Intracellular SCV-MSSA CFUs Results Delafloxacin resulted in a 1.9-log reduction in intracellular CFUs (p&lt; 0.001) at 5 hours and a 3.4 log reduction (p&lt; 0.001) at 24 hours compared to antibiotic-free control for MSSA strains (Fig 2). Similarly, levofloxacin resulted in a 1.6-log (p&lt; 0.001) and 1.9-log (p&lt; 0.001) reduction in CFUs after 5 and 24 hours, respectively. Delafloxacin was more effective at clearing intracellular bacteria than levofloxacin at 24 hours (p= 0.004). In MRSA-SCV isolates, delafloxacin demonstrated CFU reduction of 2.4-log (p&lt; 0.001) at 5 hours and 4.7-log (p&lt; 0.001) at 24 hours compared to antibiotic-free control (Fig 3). Levofloxacin demonstrated a 1.6-log (p&lt; 0.001) reduction at 5 hours and 1.5-log (p= 0.034) reduction at 24 hours. In comparison to levofloxacin, delafloxacin led to greater reductions in MRSA CFUs at both 5 hours and 24 hours of incubation, 0.85-log (p= 0.028) and 3.2-log (p&lt; 0.001) respectively.Figure 3.Intracellular SCV-MRSA CFUs Conclusion The results demonstrate delafloxacin having greater intracellular activity than levofloxacin and other comparator antibiotics against both MSSA and MRSA SCVs. These results support using delafloxacin to treat recurrent or chronic infections caused by either MSSA or MRSA SCVs and suggest that the observed efficacy may be a result of enhanced intracellular activity. Disclosures All Authors: No reported disclosures
Large Language Models on Radiation Oncology Tasks: Small Fine-Tuned Models vs. Large Vanilla Model
Wang, P. , Liu, Tianming , Wang, Peilong , Liu, Zhengliang , Holmes, Jason , Liu, Wei

Mayo Clinic

No container title available | January 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.36227/techrxiv.173808198.86649534/v1 Get It

Purpose: This study compares the performance of small, fine-tuned LLMs with the large original models on two radiation oncology clinical tasks: treatment modality selection and ICD-10 code prediction. Methods: We used data of 403 treatment modality selection cases and 377 ICD-10 code prediction cases. The models used were fine-tuned LLaMA 2 7B and Mistral 7B, as well as the larger LLaMA 3.1 70B and 405B models for comparison. We evaluated the accuracy of all models on these two tasks. Results: Both fine-tuned LLaMA 2 7B and Mistral 7B outperformed LLaMA 3.1 70B and 405B in treatment modality selection task. The fine-tuned LLaMA 2 7B and Mistral 7B models achieved accuracy comparable to the larger models in ICD-10 code prediction. Conclusions: Small models, fine-tuned with radiation oncology data, can achieve performance comparable to-or even surpass-that of larger models.
Incidence and survival trends in small bowel adenocarcinoma (SBA) from 2000-2019 in the United States.
Sears, James J. , Fiala, Mark A. , Overman, Michael J. , Fiala, Mark A , Xu, Yifei , Liu, Jingxia , McWilliams, Robert R. , Pedersen, Katrina S.

Mayo Clinic

Journal of Clinical Oncology | January 27, 2025 | Volume: 43 | Issue: 4_suppl | Pages: 801-801

10.1200/jco.2025.43.4_suppl.801 Get It

801 Background: SBA is a rare, poorly understood gastrointestinal malignancy. Adenocarcinomas are often grouped with other small bowel cancer histologies in epidemiologic and outcomes reports, which limits the ability to detect SBA-specific trends. Recent studies in European populations show increasing SBA incidence, but there are limited published data in American cohorts. Identifying trends in SBA can improve understanding of the population most at risk for developing SBA. This study describes U.S. trends in SBA incidence and outcomes from 2000 to 2019. Methods: Using the 2022 SEER research-limited dataset, we identified SBA cases and measured the incidence change from 2000-2019. We built linear regression models to evaluate changes in annual incidence by groups, including sex, race, and age of diagnosis, separately. We then compared the overall incidence and trends between subgroups. We investigated overall survival (OS) through the SEER research case listings for SBA patients diagnosed during the study period. Results: An average of 0.67 cases/100,000 SBA cases were reported annually from 2000-2019, with a median diagnosis age of 69 years. SBA incidence has increased annually by 0.3% per year from 2000-2019 (p=0.05). From 2000-2019, men were at a higher risk for SBA compared to women (p=0.02). In men, SBA cases increased at a rate of 0.004 cases/100,000/year from 2000-2019 (p=0.01) and a nonsignificant decrease in women of 0.00012 cases/100,000/year. There were no statistically significant differences in incidence or the change in incidence of SBA by race. The age-adjusted incidence was significantly higher each year between 2000 and 2019 in the > 70 cohort compared to the <70 cohort (p=0.02). Cases of SBA increased at a rate of 0.02 cases/100,000/year in adults >70 years (p=0.02). There were no differences in incidence rates in patients <70 years. There was no significant difference in OS for patients diagnosed with SBA in 2000, 2005, 2010, 2015, and 2019 (p=0.21). Conclusions: The overall annual incidence of SBA is increasing in the U.S. population. The most significant rate increases are in men and adults older than 70. In the SEER population, trends in SBA contrast with the recent rise of colorectal cancer in the young adult population, highlighting the unique nature of SBA compared to other gastrointestinal malignancies. Additionally, survival outcomes in patients diagnosed with SBA have remained stable over the past 20 years, while other malignancies have shown improvement in the same period. The small cohort size and the lack of a universal U.S. cancer registry limited this evaluation. Improved reporting of SBA cases and further research to identify risk factors are urgently needed to reduce the growing impact of SBA.
Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer
Wolf, Emily, Correia, Guilherme Sacchi de Camargo, Li, Shenduo , Zhao, Yujie , Lou, Yanyan , Wolf, Emily B , Sacchi de Camargo Correia, Guilherme, Manochakian, Rami

Mayo Clinic

Vaccines | January 27, 2025 | Volume: 13 | Issue: 2 | Pages: 128

10.3390/vaccines13020128 | PMID 40006675 Get It

Lung cancer remains the leading cause of cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, with nearly half of all patients diagnosed at an advanced stage. Immune checkpoint inhibitors (ICIs) harness the host immune system to combat malignant cells. ICIs, which target programmed death-ligand 1 (PD-L1), programmed cell death 1 (PD-1), and cytotoxic T-cell lymphocyte-4 (CTLA-4), have transformed the treatment landscape for advanced NSCLC. While a subset of patients experiences a long-term durable response, most patients will develop disease progression. New drugs targeting novel pathways are being tested in clinical trials to improve the efficacy of immunotherapy and overcome resistance patterns. This review aims to summarize the currently available ICIs for advanced NSCLC and describe emerging immunotherapies with recently published data from phase I/II clinical trials.
Circulating and Magnetic Resonance Imaging Biomarkers of Intestinal Fibrosis in Small Bowel Crohn’s Disease
Dillman, Jonathan R. , Tkach, Jean A. , Bruining, David H. , Lu, Aiming , Kugathasan, Subra , Knight‐Scott, Jack, Adler, Jeremy, Minar, Phillip , Bonkowski, Erin , Jurrell, Holden, Swanson, Scott D. , Fei, Lin , Qian, Lucia, Towbin, Alexander J. , Kocaoğlu, Murat , Anton, Christopher G. , Imbus, Rebecca, Denson, Lee A. , Kugathasan, Subra , Minar, Phillip , Dillman, Jonathan R , Fletcher, Joel G. , Alazraki, Adina , Stidham, Ryan W , Adler, Jeremy, Trapnell, Bruce C. , Lopez‐Nunez, Oscar , Collins, Margaret H. , Dudley, Jonathan A.

Mayo Clinic

Inflammatory Bowel Diseases | January 24, 2025 | Volume: 31 | Issue: 5 | Pages: 1380-1391

10.1093/ibd/izae319 | PMID 39853252 Get It

Abstract Background We previously identified circulating and MRI biomarkers associated with the surgical management of Crohn’s disease (CD). Here we tested associations between these biomarkers and ileal resection inflammation and collagen content. Methods Fifty CD patients undergoing ileal resection were prospectively enrolled at 4 centers. Circulating CD64, extracellular matrix protein 1 (ECM1), GM-CSF autoantibodies (GM-CSF Ab), and fecal calprotectin were measured by ELISA. Ileal 3-dimensional magnetization transfer ratio (3D MTR), modified Look-Locker inversion recovery (MOLLI) T1 relaxation, diffusion-weighted intravoxel incoherent motion (IVIM), and the simplified magnetic resonance index of activity (sMaRIA) were measured by MRI. Ileal resection specimen acute inflammation was graded, and collagen content was measured quantitatively using second harmonic imaging microscopy. Associations between biomarkers and ileal collagen content were tested. Results Median (interquartile range [IQR]) age was 19.5 (16-33) years. We observed an inverse relationship between ileal acute inflammation and collagen content (r = −0.39 [95% confidence interval {CI}: −0.61, −0.10], P = .008). Most patients (33 [66%]) received biologics, with no variation in collagen content with treatment exposures. In the univariate analysis, CD64, GM-CSF Ab, fecal calprotectin, and sMaRIA were positively associated with acute inflammation and negatively associated with collagen content (P &lt; .1). The multivariable model for ileal collagen content (R2 = 0.31 [95% CI: 0.11, 0.52]) included log CD64 (β = −.27; P = .19), log ECM1 (β = .47; P = .06), log GM-CSF Ab (β = −.15; P = .01), IVIM f (β = .29, P = .10), and IVIM D* (β = 1.69, P = .13). Conclusions Clinically available and exploratory circulating and MRI biomarkers are associated with the degree of inflammation versus fibrosis in CD ileal resections. With further validation, these biomarkers may be used to guide medical and surgical decision-making for refractory CD.